Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
A Phase 2 Open Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination with Ruxolitinib in Subjects with Myelofibrosis (REFINE)
NCT Number:
NCT03222609
Phase:
II
Protocol Type:
Treatment
Age Group:
Adults
Disease Sites:
Other Hematopoietic
Study Objectives:
This is a Phase 2 open-label, multicenter study evaluating tolerability and efficacy of navitoclax alone or when added to ruxolitinib in participants with myelofibrosis.
Study Documents
(MUSC NetID required for document access)